14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ENTA ranks #14947 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Enanta Pharmaceuticals Stock Forecast NASDAQ:ENTA

$74.81 (-3.67%)

Volume: 136k

Closed: Dec 08, 2021

Hollow Logo Score: -1.624

Enanta Pharmaceuticals Stock Forecast

$74.81 (-3.67%)

Volume: 136k

Closed: Dec 08, 2021

Score Hollow Logo -1.624

Enanta Pharmaceuticals Stock Forecast NASDAQ:ENTA

Price Target and Analyst Ratings

Most Recent Rating

On Nov 24, 2021 "Oppenheimer" gave "$55.00 - $73.00" rating for ENTA. The price target was set to $86.76+0.3%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-11-24 $55.00 - $73.00 Target Raised by Oppenheimer $86.89 $86.76+0.3%
2021-11-23 $111.00 - $116.00 Target Raised by JMP Securities $86.50 $83.63+11.2%
2021-11-23 $107.00 - $101.00 Target Lowered by Roth Capital $86.50 $84.74+12.7%
2021-11-23 $92.00 - $85.00 Target Lowered by SVB Leerink $86.50 $80.47+7.0%
2021-11-23 $111.00 - $116.00 Reiterated by JMP Securities $86.50 $80.47+7.0%
2021-11-08 $71.00 - $130.00 Target Raised by Robert W. Baird $94.24 $97.69+0.3%
2021-11-08 $77.00 - $121.00 Target Raised by JMP Securities $94.24 $97.69+0.3%
2021-11-08 $55.00 - $92.00 Target Raised by SVB Leerink $94.24 $97.69+0.3%
2021-10-20 $58.00 - $74.00 Target Raised by Royal Bank of Canada $72.00 $71.07+1.8%
2021-10-20 $73.00 - $77.00 Target Raised by JMP Securities $72.00 $71.07+1.8%
2021-10-20 $73.00 - $78.00 Reiterated by JMP Securities $72.00 $71.60+2.6%
2021-10-06 Initiated by Jefferies Financial Group $61.20 $61.20+1.1%
2021-09-09 $55.00 Initiated by SVB Leerink $55.82 $57.17+0.1%
2021-08-06 $70.00 - $77.00 Target Raised by JMP Securities $44.85 $46.25+8.9%
2021-08-06 $52.00 - $50.00 Target Lowered by Royal Bank of Canada $44.85 $46.17→0.2%
2021-02-09 In-Line - Sector Perform Target Raised by Royal Bank of Canada $54.73 $47.00 → $53.00
2021-01-29 Underweight - Neutral Upgraded by JPMorgan Chase & Co. $48.06 $55.00
2021-01-29 Underweight - Neutral Upgraded by JPMorgan Chase & Co. $48.06 $44.00 → $55.00
2020-11-24 Sector Perform Target Lowered by Royal Bank of Canada $42.89 $52.00 → $45.00
2020-11-23 Underperform Initiated by Evercore ISI $43.67
2020-10-26 Buy Target Raised by Roth Capital $43.50 $104.00 → $107.00
2020-09-23 Hold Reiterated by Oppenheimer $43.36 $55.00
2020-08-27 Buy Initiated by Roth Capital $49.67
2020-08-25 Overweight Initiated by Piper Sandler $50.64
2020-08-06 Hold Reiterated by Royal Bank of Canada $46.31
2020-08-04 Hold Initiated by Oppenheimer $47.69 $55.00
2020-07-27 Market Perform - Outperform Upgraded by JMP Securities $50.32 $70.00
2020-05-07 Hold Reiterated by Oppenheimer $50.68 $62.00
2020-04-08 Hold Reiterated by Royal Bank of Canada $52.17 $49.00

ENTA Stock Trend

Given the current short-term trend, the stock is expected to rise 53.17% during the next 3 months and, with a 90% probability hold a price between $114.59 and $169.71 at the end of this 3-month period.

Data

Date Bottom Mid Top
2021-12-10 $75.42 $93.42 $111.41
2021-12-13 $76.03 $94.03 $112.02
2021-12-14 $76.64 $94.64 $112.63
2021-12-15 $77.25 $95.25 $113.24
2021-12-16 $77.86 $95.86 $113.85
2021-12-17 $78.47 $96.47 $114.46
2021-12-20 $79.08 $97.08 $115.08
2021-12-21 $79.69 $97.69 $115.69
2021-12-22 $80.30 $98.30 $116.30
2021-12-23 $80.92 $98.91 $116.91
2021-12-27 $81.53 $99.52 $117.52
2021-12-28 $82.14 $100.13 $118.13
2021-12-29 $82.75 $100.74 $118.74
2021-12-30 $83.36 $101.35 $119.35
2021-12-31 $83.97 $101.96 $119.96
2022-01-03 $84.58 $102.57 $120.57
2022-01-04 $85.19 $103.18 $121.18
2022-01-05 $85.80 $103.80 $121.79
2022-01-06 $86.41 $104.41 $122.40
2022-01-07 $87.02 $105.02 $123.01
2022-01-10 $87.63 $105.63 $123.62
2022-01-11 $88.24 $106.24 $124.23
2022-01-12 $88.85 $106.85 $124.84
2022-01-13 $89.46 $107.46 $125.45
2022-01-14 $90.07 $108.07 $126.06
2022-01-17 $90.68 $108.68 $126.67
2022-01-18 $91.29 $109.29 $127.29
2022-01-19 $91.90 $109.90 $127.90
2022-01-20 $92.52 $110.51 $128.51
2022-01-21 $93.13 $111.12 $129.12

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease i... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT